Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1978 2
1979 1
1980 1
1981 4
1982 6
1983 2
1984 2
1985 1
1986 1
1988 1
1989 3
1990 3
1991 6
1992 4
1993 4
1994 2
1995 5
1996 4
1997 6
1998 6
1999 4
2000 2
2001 5
2002 6
2003 4
2004 8
2005 10
2006 14
2007 15
2008 18
2009 24
2010 17
2011 23
2012 17
2013 27
2014 18
2015 15
2016 17
2017 24
2018 21
2019 28
2020 21
2021 25
2022 31
2023 31
2024 36
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Results by year

Filters applied: . Clear all
Page 1
[Chronic diarrhoea: Definition, classification and diagnosis].
Fernández-Bañares F, Accarino A, Balboa A, Domènech E, Esteve M, Garcia-Planella E, Guardiola J, Molero X, Rodríguez-Luna A, Ruiz-Cerulla A, Santos J, Vaquero E. Fernández-Bañares F, et al. Among authors: domenech e. Gastroenterol Hepatol. 2016 Oct;39(8):535-59. doi: 10.1016/j.gastrohep.2015.09.018. Epub 2015 Nov 21. Gastroenterol Hepatol. 2016. PMID: 26610769 Review. Spanish.
Reviewing the therapeutic role of budesonide in Crohn's disease.
López-Sanromán A, Clofent J, Garcia-Planella E, Menchén L, Nos P, Rodríguez-Lago I, Domènech E. López-Sanromán A, et al. Among authors: domenech e. Gastroenterol Hepatol. 2018 Aug-Sep;41(7):458-471. doi: 10.1016/j.gastrohep.2018.05.013. Epub 2018 Jul 12. Gastroenterol Hepatol. 2018. PMID: 30007787 Free article. Review. English, Spanish.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.
D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. D'Amico F, et al. Among authors: domenech e. United European Gastroenterol J. 2021 May;9(4):451-460. doi: 10.1002/ueg2.12069. Epub 2021 May 7. United European Gastroenterol J. 2021. PMID: 33961734 Free PMC article.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM. Zinzani PL, et al. Among authors: domenech ed. Lancet Oncol. 2024 Dec;25(12):1602-1613. doi: 10.1016/S1470-2045(24)00503-5. Epub 2024 Oct 29. Lancet Oncol. 2024. PMID: 39486433 Clinical Trial.
Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry.
Iborra M, Caballol B, Garrido A, Huguet JM, Mesonero F, Ponferrada Á, Arias García L, Boscá Watts MM, Fernández Prada SJ, Brunet Mas E, Gutiérrez Casbas A, Cerrillo E, Ordás I, Ruiz L, García de la Filia I, Escobar Ortiz J, Sicilia B, Ricart E, Domènech E, Nos P. Iborra M, et al. Among authors: domenech e. J Crohns Colitis. 2025 Jan 11;19(1):jjae127. doi: 10.1093/ecco-jcc/jjae127. J Crohns Colitis. 2025. PMID: 39171615
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M; EXIT Study group of GETECCU. Gisbert JP, et al. Among authors: domenech e. Gut. 2025 Feb 6;74(3):387-396. doi: 10.1136/gutjnl-2024-333385. Gut. 2025. PMID: 39794921 Free PMC article. Clinical Trial.
459 results